Risk of cardiovascular disease from cumulative cigarette use and the impact of smoking intensity

Epidemiology

Volumn 27, Issue 3, 2016, Pages 395-404

  Lubin, Jay H ^a   Couper, David ^b   Lutsey, Pamela L ^c   Woodward, Mark ^d,e,f   Yatsuya, Hiroshi ^g   Huxley, Rachel R ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SMOKING CESSATION; SMOKING HABIT; AGED; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; POISSON DISTRIBUTION; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TOBACCO; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK; RISK FACTORS; SMOKING; SMOKING CESSATION; TIME FACTORS; TOBACCO PRODUCTS; UNITED STATES;

EID: 84964034109     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/eDe.0000000000000437     Document Type: Article

References (41)

1. Benowitz NL. cigarette smoking and cardiovascular disease: pathophysi-ology and implications for treatment. Prog Cardiovasc Dis. 2003;46: 91-111.
2. Burns DM. epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11-29.
3. Law MR, Wald NJ. environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis. 2003;46:31-38.
4. Benowitz NL, Pomerleau O F, Pomerleau CS, Jacob P iii. nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003;5:621-624.
5. Csordas A, Bernhard D. the biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol. 2013;10:219-230.
6. Pant R, Marok R, Klein LW. Pathophysiology of coronary vascular remodeling: relationship with traditional risk factors for coronary artery disease. Cardiol Rev. 2014;22:13-16.
7. Ambrose JA, Barua RS. the pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43: 1731-1737.
8. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Washington, Dc: U.S. Department of Health and Human Services, centers for Disease control and Prevention, national center for chronic Disease Prevention and Health Promotion, Offce on Smoking and Health, Superintendent of Documents, U.S. government Printing Offce; 2010.
9. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General. atlanta, ga: U.S. Department of Health and Human Services, centers for Disease control and Prevention, national center for chronic Disease Prevention and Health Promotion, Offce on Smoking and Health, Superintendent of Documents. Washington, Dc: U.S. government Printing Offce; 2014.
10. Dietrich T, Hoffmann K. a comprehensive index for the modeling of smoking history in periodontal research. J Dent Res. 2004;83:859-863.
11. Leffondré K, Abrahamowicz M, Xiao Y, Siemiatycki J. Modelling smoking history using a comprehensive smoking index: application to lung cancer. Stat Med. 2006;25:4132-4146.
12. Peto J. that the effects of smoking should be measured in pack-years: misconceptions 4. Br J Cancer. 2012;107:406-407.
13. Lubin JH, Caporaso NE. Misunderstandings in the misconception on the use of pack-years in analysis of smoking. Br J Cancer. 2013;108: 1218-1220.
14. Thomas DC. invited commentary: is it time to retire the "pack-years" variable? Maybe not! Am J Epidemiol. 2014;179:299-302.
15. Aric investigators. the atherosclerosis risk in communities (aric) study: design and objectives. Am J Epidemiol. 1989;129:687-702.
16. Rosamond WD, Chambless LE, Heiss G, et al. twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation. 2012;125:1848-1857.
17. White AD, Folsom AR, chambless LE, et al. community surveillance of coronary heart disease in the atherosclerosis risk in communities (aric) study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
18. Huxley RR, Yatsuya H, Lutsey PL, Woodward M, Alonso A, Folsom AR. impact of age at smoking initiation, dosage, and time since quitting on cardiovascular disease in african americans and whites: the atherosclerosis risk in communities study. Am J Epidemiol. 2012;175:816-826.
19. Lunn M, Mcneil D. applying cox regression to competing risks. Biometrics. 1995;51:524-532.
20. Kalbfeisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. new York, nY: Wiley; 2015.
21. Akaike H. a new look at the statistical model identifcation. IEEE Trans Automatic Control. 1974;19:716-723.
22. Preston DL, Lubin JH, Pierce DA, Mcconney ME. Epicure User's Guide. Seattle, Wa: HiroSoft international corporation; 2006.
23. Law MR, Morris JK, Watt HC, Wald NJ. the dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. Br J Cancer. 1997;75:1690-1693.
24. Wu D, Nishimura N, Kuo V et al. activation of aryl hydrocarbon receptor induces vascular infammation and promotes atherosclerosis in apolipo-protein e-/-mice. Arterioscler Thromb. 2011;31:1260-1237.
25. Lewtas J. air pollution combustion emissions: characterization of causative agents and mechanisms associated with cancer, reproductive, and cardiovascular effects. Mutat Res. 2007;636:95-133.
26. Alshaarawy O, Zhu M, Ducatman A, Conway B, Andrew ME. Polycyclic aromatic hydrocarbon biomarkers and serum markers of infamma-tion. a positive association that is more evident in men. Environ Res. 2013;126:98-104.
27. Phillips DH. Smoking-related Dna and protein adducts in human tissues. Carcinogenesis. 2002;23:1979-2004.
28. Lewtas J, Walsh D, Williams R, Dobiás L. air pollution exposure-Dna adduct dosimetry in humans and rodents: evidence for non-linearity at high doses. Mutat Res. 1997;378:51-63.
29. Joseph AM, Hecht SS, Murphy SE, et al. relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev. 2005;14:2963-2968.
30. Blackford AL, Yang G, Hernandez-avila M, et al. cotinine concentration in smokers from different countries: relationship with amount smoked and cigarette type. Cancer Epidemiol Biomarkers Prev. 2006;15: 1799-1804.
31. Campuzano JC, Hernandez-avila M, Jaakkola MS, et al. Determinants of salivary cotinine levels among current smokers in Mexico. Nicotine Tob Res. 2004;6:997-1008.
32. Etter JF, Perneger TV. Measurement of self reported active exposure to cigarette smoke. J Epidemiol Community Health. 2001;55:674-680.
33. Lewis SJ, Cherry NM, Mclniven R, Barber P V, Wilde K, Povey AC. cotinine levels and self-reported smoking status in patients attending a bronchoscopy clinic. Biomarkers. 2003;8:218-228.
34. O'connor RJ, Giovino GA, Kozlowski LT, et al. changes in nicotine intake and cigarette use over time in two nationally representative cross-sectional samples of smokers. Am J Epidemiol. 2006;164:750-759.
35. Olivieri M, Poli A, Zuccaro P, et al. tobacco smoke exposure and serum cotinine in a random sample of adults living in Verona, italy. Arch Environ Health. 2002;57:355-359.
36. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev. 1997;6:783-790.
37. Lubin JH, Caporaso N, Hatsukami DK, Joseph AM, Hecht SS. the association of a tobacco-specifc biomarker and cigarette consumption and its dependence on host characteristics. Cancer Epidemiol Biomarkers Prev. 2007;16:1852-1857.
38. Woodward M, tunstall-Pedoe H, Smith WC, Tavendale R. Smoking characteristics and inhalation biochemistry in the Scottish population. J Clin Epidemiol. 1991;44:1405-1410.
39. Xia Y, Bernert JT, Jain RB, Ashley DL, Pirkle JL. tobacco-specifc ni-trosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nnal) in smokers in the United States: nHaneS 2007-2008. Biomarkers. 2011;16:112-119.
40. Nagano T, Shimizu M, Kiyotani K, et al. Biomonitoring of urinary coti-nine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. Int J Environ Res Public Health. 2010;7:2953-2964.
41. Lubin JH, Caporaso N, Wichmann HE, Schaffrath-rosario A, Alavanja MC. cigarette smoking and lung cancer: modeling effect modifcation of total exposure and intensity. Epidemiology. 2007;18:639-648.